EpiCept’s Nasdaq listing endangered
-
- April
- 8
EpiCept Corp. of Eastview said yesterday that its listing on the Nasdaq market is endangered. The drug researcher said it is out of compliance with Nasdaq rules that require a market cap of $35 million for 10 consecutive trading days. EpiCept said it is working to regain compliance by a May 5 deadline.
This entry was posted
on Tuesday, April 8th, 2008 at 5:20 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
Advertisement
